Business Context and Reporting Period
Company: American Shared Hospital Services (ASHS)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2024
Business Overview: ASHS provides turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy. Operations are divided into two reportable segments: Leasing (medical equipment leasing to hospitals) and Retail (direct patient services at owned facilities).
Key Event: On May 7, 2024, the Company completed the acquisition of a 60% interest in three Rhode Island radiation therapy facilities (the "RI Acquisition") for $2.85 million.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2024 | Nine Months Ended Sept 30, 2024 | Nine Months Ended Sept 30, 2023 |
|---|---|---|---|
| Total Revenue | $6,999,000 | $19,271,000 | $15,627,000 |
| Gross Margin | $1,370,000 (19.6%) | $5,981,000 (31.0%) | $6,528,000 (41.8%) |
| Operating (Loss) Income | $(889,000) | $(975,000) | $(137,000) |
| Net Income (Loss) | $(410,000) | $3,423,000 | $88,000 |
| Net Income Attributable to ASHS | $(207,000) | $3,514,000 | $195,000 |
| Diluted EPS | $(0.03) | $0.54 | $0.03 |
| Cash and Cash Equivalents | $13,827,000 | $13,827,000 | $14,537,000 (End of Period 2023) |
| Total Debt (Current + Long-Term) | $18,875,000 | $18,875,000 | $13,625,000 (End of Period 2023) |
Note: Total Debt includes $4.5M line of credit, $3.557M current portion of long-term debt, and $10.818M long-term debt.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 36.1% for the nine months ended Sept 30, 2024, compared to the prior year. This was driven by a 219.9% increase in Retail segment revenue ($7.8M vs $2.4M) due to the RI Acquisition and the new Puebla, Mexico facility.
- Leasing Segment Decline: Leasing revenue decreased 11.7% for the nine-month period ($11.5M vs $13.0M) due to lower Gamma Knife procedure volumes, contract expirations, and equipment downtime.
- Profitability Impact: While the nine-month net income increased significantly to $3.4M, this was primarily due to a $3.942 million bargain purchase gain recorded from the RI Acquisition. Excluding this gain, the Company reported an operating loss of $975,000 for the nine months.
- Cost Structure: Costs of revenue increased 46.1% year-over-year for the nine-month period, largely due to operating costs from newly acquired facilities and increased depreciation from equipment upgrades.
- Balance Sheet: Total assets grew from $48.2M to $63.3M, driven by the acquisition of property and equipment and the RI Acquisition. Total liabilities increased from $21.9M to $31.4M.
Guidance, Outlook, and Risks
- Capital Commitments: The Company has committed to purchase and install four Gamma Knife Esprit systems and two LINAC systems totaling $13.383 million. Additionally, service commitments total $13.712 million. The Company intends to finance these projects.
- Liquidity: As of September 30, 2024, the Company held $14.1 million in cash and restricted cash. It has a $7.0 million revolving line of credit with $4.5 million currently drawn. Management believes cash on hand and operations are sufficient to meet obligations for the next 12 months.
- Debt Covenants: The Company is in compliance with its Credit Agreement covenants, including a minimum fixed charge coverage ratio of 1.25 and a maximum funded debt to EBITDA ratio of 3.0.
- Risks:
- Reimbursement Rates: Potential implementation of the Radiation Oncology Alternative Payment Model (RO APM) by CMS could alter payment methodologies.
- Financing Availability: No assurance that financing will be available for future capital commitments on acceptable terms.
- Volume Dependence: Revenue is highly dependent on procedure volumes, which were negatively impacted by staffing shortages and equipment downtime in the leasing segment.
Investor Verification Checklist
- Bargain Purchase Gain: Verify the sustainability of the $3.9M gain from the RI Acquisition, as it is a non-recurring item that significantly inflated nine-month net income.
- Leasing Segment Trends: Monitor the trajectory of Gamma Knife procedure volumes and the impact of contract expirations on the core leasing business.
- Capital Expenditure Funding: Assess the Company's ability to secure financing for the $13.4M in equipment commitments without diluting shareholders or breaching debt covenants.
- Working Capital: Review the $1.5M decrease in working capital and the increase in accounts receivable ($8.6M) to ensure collection efficiency in the new retail facilities.
- Related Party Transactions: Note the significant reliance on Elekta (a related party) for equipment purchases and maintenance, with related party liabilities totaling $4.1M.